CTLA4 and neoplasm: Moreover, TNBC-bearing mice treated with the TGF-β inhibitor TRANILAST combined with the nanomedicine DOXIL as a vessel normalizing strategy, show a marked reduction in extracellular matrix components and an increase in intratumor vessel diameter and pericyte coverage: this leads to the infiltration of T cells and M1 macrophages into the tumor and improves the efficacy of anti-PD-1/anti-CTLA-4 antibodies [138].